Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Exclusive: Pfizer...

    Exclusive: Pfizer weighs sale or spin off of consumer health unit - sources

    Written by supriya kashyap kashyap Published On 2016-11-10T13:32:12+05:30  |  Updated On 17 Aug 2021 11:58 AM IST

    U.S. drugmaker Pfizer Inc is evaluating a potential sale or spin-off of its consumer health division that could value the unit at as much as $14 billion, people familiar with the matter said.


    A Pfizer exit from the consumer health business, which includes lip balm Chapstick and painkiller Advil, would be one of its biggest corporate moves since abandoning a $160 billion deal to buy Irish drug maker Allergan Inc earlier this year.


    The deliberations are still in a preliminary stage and the New York-based pharmaceutical company may opt to retain the business, the people said.


    The people asked not to be named because they were not authorized to speak publicly about the matter. Pfizer declined to comment.


    Pfizer earlier this year decided against splitting itself into two companies, one housing its patent-protected drug business and one containing its generics business. Pfizer began openly planning for a possible split in early 2014, as a way to simplify its portfolio.


    In Pfizer's most recent quarterly earnings call, Chief Executive Officer Ian Read said that Pfizer was continually evaluating whether its consumer business, along with other business lines, was worth more in or outside the company.


    The consumer business had annual sales of about $3.5 billion.


    If a sale or spin-off went ahead, Pfizer would be the latest pharmaceutical company to sell its consumer business to slim down its portfolio. Consumer drugs sold over the counter have far lower margins than prescription drugs.


    In 2014, Merck & Co Inc sold its consumer care business, including the MiraLAX laxative, to Germany's Bayer AG in a $14.2 billion deal. In early 2015, drug makers GlaxoSmithKline PLC and Novartis AG agreed to merge their consumer health businesses through a joint venture, run by Glaxo as part of a $20 billion asset swap.


    Reckitt Benckiser Group Plc's CEO, Rakesh Kapoor, last year said it would consider buying Pfizer's consumer unit if it were to come up for sale.


    Pfizer has been one of most active acquirers in an otherwise sluggish year for pharmaceutical M&A. In August it bought cancer drug maker Medivation for $14 billion. Earlier this year, it acquired dermatology company Anacor Pharmaceuticals for $5.2 billion.

    Allerganconsumer healthGlaxoSmithKlinelip balm ChapstickMedivationMerck & Copainkiller AdvilPfizerRakesh KapoorReckitt Benckiser
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok